2012, Number 4
PDF size: 383.48 Kb.
ABSTRACTThere is a high prevalence of prostate cancer in Mexico as well as worldwide, mainly affecting older males. Thanks to prostate specific antigen measurements and physical examination, this cancer is being diagnosed at earlier stages in which curative treatments can be offered. However, patients with advanced stage disease are subject to palliative therapy, the aim of which is to diminish disease symptoms and progression. Androgen blockade, whether surgical or pharmacologic, is the cornerstone of this therapeutic intervention and is used according to different modalities and regimens. Pharmacologic androgen blockade involves a wide variety of drugs that have different action mechanisms that include: estrogenic compounds, antiandrogens (steroidal and nonsteroidal), LHRH agonists, LHRH antagonists, and steroidogenesis inhibitors. These pharmacologic groups have advantages and disadvantages in relation to their response, effectiveness, adverse effects, and cost, which will be discussed in this paper. Therefore it is important that prostate cancer treatment be individualized according to each patient’s needs. The ongoing research in this area has led to the development of other therapeutic alternatives (immunotherapy and chemotherapy) and new therapeutic targets in the treatment of prostate cancer.
Tyrrell CJ, Altwein JE, Klippel F, et al. Comparison of an LH-RH Analogue (Goeserelin Acetate, ‘Zoladex’) with Combined Androgen Blockade in Advanced Prostate Cancer: Final Survival Results of an International Multicentre Randomized-Trial. International Prostate Cancer Study Group. Eur Urol 2000;37(2):205-211.
Kelly WK, Halabi S, Carducci MA, et al. A Randomized, Double Blind, Placebo- Controlled Phase III Trial Comparing Docetaxel, Prednisone, and Placebo with Docetaxel, Prednisone and Bevacizumab in Men with Metastatic Castration- Resistant Prostate Cancer (Mcrpc): Survivial Results Of CALGB 90401. J Clin Oncol 2012;30(13):1534-1540.